Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014456 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00014456 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 35 participants.
The verdict
NCT00014456, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have advanced solid tumors.
Interventions
- DRUG docetaxel
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2000-03 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014456
The ClinicalTrials.gov registry entry for NCT00014456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00014456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014456 about?
NCT00014456 is a clinical study titled "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00014456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2000-03. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00014456?
The interventions under investigation include: docetaxel (DRUG), filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00014456?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.